Orphan Drug Catalyst Pushing DARA Shares Toward Possible Technical Break-Out

Orphan Drug Catalyst Pushing DARA Shares Toward Possible Technical Break-Out 
LOS ANGELES, CA -- (Marketwire) -- 02/19/13 --   DARA Biosciences
(NASDAQ: DARA), a specialty pharmaceutical company focused on
oncology and oncology supportive care products, is expecting to hear
soon on the status of its Orphan Drug application submitted to The
Food and Drug Administration (FDA) in November of last year for its
drug KRN5500, which is being studied for the treatment of chronic
chemotherapy-induced peripheral neuropathy (CCIPN). 
KRN5500 is a novel, spicamycin-derived, non-opioid-non-narcotic
intravenous pain therapeutic with promising clinical trial results in
patients with chemotherapy-induced peripheral neuropathy (CIPN). 
More than 70% of patients treated with taxane-class or platinum-class
chemotherapeutic agents; at least 25% of those treated with
vinca-class agents; and significant numbers of those treated with
Thalomid(R), Revlimid(R), Velcade(R), and a variety of other cancer
drugs experience CIPN, which can be disabling and adversely affect
quality of life. 
There is presently no FDA-approved drug for CIPN. 
In October, 2011, the U.S. FDA granted KRN-5500 Fast Track
designation for CIPN, an indication with a market potential estimated
at $2.5B. 
Summary of Phase 2a clinical trial results: 

--  "A Spicamycin Derivative (KRN5500) Provides Neuropathic Pain Relief in
    Patients with Advanced Cancer: A Placebo-Controlled, Proof-of-Concept
    Trial"; Journal of Pain and Symptom Management
--  Patients had failed on at least two previous pain therapeutics
--  KRN5500 met primary endpoints: reduction of pain and safety
--  Significantly more effective than placebo (p=0.03)
--  Transient and manageable GI side effects

The stock is trading in a manner that hints at positive news concerning
the Orphan Drug status application. 
For example, the stock chart for DARA is forming a cup and handle
breakout pattern with resistance at $1.20. Once past this level, the
near term price target indicates a test of the prior high of $1.38.
Measuring the cup and handle break indicates a move over $2 in the
coming months.  
Disclosure: Author Scott Matusow is Long DARA.  
The full version of this report com
plete with a technical analysis
chart can be found here:  
Healthcare investors and Biotech traders interested in accessing
BioMedReports' new complete database of clinical trials and upcoming
FDA and world-wide regulatory decisions which can be used to make
more profitable trades and see upcoming catalysts can go to:
Follow Us 
News developments and live healthcare sector updates are available
constantly via twitter at: http://twitter.com/BioMedReports 
About BioMedReports.Com 
BioMedReports is a news and research portal covering financial
biotech news for the entire Healthcare Sector of the market.
BioMedReports is not paid or compensated to report the news and
developments of publicly traded companies. BioMedReports sells a
premium product for subscribers and full disclosures and information
about the stocks and news mentioned in this news release are
available at BioMedReports.Com 
Media Contacts Only:
M. Davila
Assistant Editor
e-mail: info@biomedreports.com 
Press spacebar to pause and continue. Press esc to stop.